Cancer Medicine最新文献

{"title":"Cancer Fatalism Among Asian American Adults by Origin Group, 2012–2022","authors":"Justine Liu,&nbsp;Yenan Zhu,&nbsp;Ryan Suk,&nbsp;Milkie Vu","doi":"10.1002/cam4.70738","DOIUrl":"https://doi.org/10.1002/cam4.70738","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Backgrounds</h3>\u0000 \u0000 <p>Cancer fatalism, the belief that cancer is predetermined and unpreventable, is associated with lower uptake of cancer prevention. Little is known about cancer fatalism prevalence within various Asian origin groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a disaggregated analysis of cancer fatalism among Chinese, Filipino, Indian, Vietnamese, and other Asian respondents using the 2012–2022 Health Information National Trends Survey. Pairwise comparisons were conducted to assess differences between each racial and ethnic group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significantly lower proportions of Indian respondents (40.36%) endorsed the statement “It seems like everything causes cancer,” when compared with Vietnamese (74.59%, p = 0.0002) and Filipino (75.18%, p = 0.0009) respondents. Lower proportions of Indian and Chinese respondents endorsed the statement “There's not much you can do to lower your chances of getting cancer” when compared with Vietnamese and Filipino respondents, though these differences were not significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Findings highlight the heterogeneity among Asian origin groups and emphasize the importance of disaggregated data collection by origin group, which can inform culturally tailored interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma","authors":"Sijia Yan,&nbsp;Xi Ming,&nbsp;Rubing Zheng,&nbsp;Xiaojian Zhu,&nbsp;Yi Xiao","doi":"10.1002/cam4.70764","DOIUrl":"https://doi.org/10.1002/cam4.70764","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>As a rapidly developing therapeutic method, targeted therapy plays an important role in the treatment of multiple myeloma. In recent years, mature B cell antigen-targeting therapy has brought new hope for patients with refractory/relapsed disease. While an increasing number of patients with relapse are exposed to this type of drug, changing the therapeutic target may be an effective strategy for patients with relapse/refractory multiple myeloma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The expression of G protein-coupled receptor, class C Group 5 member D (GPRC5D), on the surface of myeloma tumor cells makes it a possible target for relapse/refractory multiple myeloma therapy, and relevant studies are in progress.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results &amp; Conclusions</h3>\u0000 \u0000 <p>The review aims to systematically summarize the current advancements in GPRC5D-targeted therapies for multiple myeloma, thereby providing valuable insights and a foundation for future studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70764","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Mechanisms and Biomarkers of Breast Cancer Invasion and Migration: An Explainable Gene–Pathway–Compounds Neural Network","authors":"Xia Qian,&nbsp;Dandan Sun,&nbsp;Yichen Ma,&nbsp;Ling Qiu,&nbsp;Jie Wu","doi":"10.1002/cam4.70769","DOIUrl":"https://doi.org/10.1002/cam4.70769","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Backgrounds</h3>\u0000 \u0000 <p>Exploring the molecular features that drive breast cancer invasion and migration remains an important biological and clinical challenge. In recent years, the use of interpretable machine learning models has enhanced our understanding of the underlying mechanisms of disease progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we present a novel gene–pathway–compound-related sparse deep neural network (GPC-Net) for investigating breast cancer invasion and migration. The GPC-Net is an interpretable neural network model that utilizes molecular data to predict cancer status. It visually represents genes, pathways, and associated compounds involved in these pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with other modeling methods, GPC-Net demonstrates superior performance. Our research identifies key genes, such as ADCY8, associated with invasive breast cancer and verifies their expression in breast cancer cells. In addition, we conducted a preliminary exploration of several pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GPC-Net is among the pioneering deep neural networks that incorporate pathways and compounds, aiming to balance interpretability and performance. It is expected to offer a more convenient approach for future biomedical research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70769","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Systemic Immunity-Inflammation Index (SII) and Fatigue, Cancer, and Cancer-Related Fatigue: Insights From NHANES (2005–2018)","authors":"Li Sun,&nbsp;Yanling Wu,&nbsp;Lydia Idowu Akinyemi,&nbsp;Zhiqiu Cao,&nbsp;Zhanhong Fan,&nbsp;Huahua Liu,&nbsp;Ziyi Yang,&nbsp;Leilei Zhang,&nbsp;Feng Zhang","doi":"10.1002/cam4.70777","DOIUrl":"https://doi.org/10.1002/cam4.70777","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the association between the systemic immunity-inflammation index (SII) and fatigue, cancer, and cancer-related fatigue (CRF) populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018 provided data for this retrospective cross-sectional study. By dividing the platelet count by the neutrophil count and the lymphocyte count, SII was calculated. Participants were categorized into four groups: normal, fatigue, cancer, and cancer-related fatigue (CRF), with the normal group serving as the reference. Binary logistic regression was applied to assess the correlations. The dose–response relationship between SII and outcomes in the four groups was evaluated using restricted cubic splines. Use threshold effect analysis to determine the optimal SII value for each of the three groups. Stratified and subgroup analyses were performed based on sociodemographic factors and confounders, with specific attention to fatigue severity levels (mild, moderate, severe) in the fatigue and CRF groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data analysis included a total of 32,491 participants, including 14,846 in the normal group, 14,581 in the fatigue group, 1520 in the cancer group, and 1544 in the CRF group. The results of binary logistic regression showed that SII was positively correlated with the fatigue group (1.43[1.33, 1.55]), cancer group (1.67 [1.43, 1.95]) and CRF group (1.93 [1.66, 2.25]). Restricted cubic spline analysis revealed a linear relationship between SII and outcomes. The threshold values (k) for each of these groups were identified as 464.78 × 10³ cells/μL, 448.97 × 10³ cells/μL, and 454.65 × 10³ cells/μL, respectively. Stratified analysis indicates that most groups exhibit significant differences. The subgroup analysis indicated that fatigue severity increased with higher SII levels, with the CRF group exhibiting the highest rate of severe fatigue (171% increase).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SII is positively correlated with fatigue, cancer, and CRF in a linear way. Higher SII values are associated with greater fatigue, particularly in the CRF population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70777","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Oncogenic Role of UBXN1 in Gastric Cancer Is Attributed to the METTL16-Mediated m6A Methylation and Histone Modifications","authors":"Kesong Shi,&nbsp;Yani Chen,&nbsp;Tian Gao,&nbsp;Hua Guo,&nbsp;Xinyao Fu,&nbsp;Yuan Wu,&nbsp;Haiquan Yu","doi":"10.1002/cam4.70772","DOIUrl":"https://doi.org/10.1002/cam4.70772","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple epigenetic regulatory mechanisms are crucial in tumorigenesis and development. However, the synergistic relationship between N6-methyladenosine (m6A) and histone modifications in regulating gene expression of gastric cancer (GC) requires further investigation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Here, based on the microarray, RNA-seq, and survival analysis data, the m6A methyltransferase METTL16 was identified as a potential tumorigenic factor of GC. The silence of METTL16 suppresses the malignant phenotype of GC cells, and the NF-κB pathway was activated. By using the weighted correlation network analysis (WGCNA) and integrating RNA-seq and MeRIP-seq data, it was found that METTL16 is significantly positively correlated with UBX domain protein 1 (UBXN1). Furthermore, through the MeRIP-qPCR and dual-luciferase reporter assays, we found that knocking down METTL16 reduced the m6A modification level of the UBXN1 coding sequence in GC. Interestingly, the silencing of METTL16 also downregulated UBXN1 expression by promoting H3K36me3 modification at the UBXN1 promoter. Subsequent investigations found that the silencing of METTL16 upregulated the expression of the major H3K36me3 methyltransferase SETD2 in GC cells by methylating the m6A site in the mRNA coding sequence of SETD2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings demonstrate the spatio-temporal regulation of UBXN1 expression in GC cells by METTL16 through a combination of transcriptional and post-transcriptional mechanisms. The synergistic interplay of these various epigenetic mechanisms provides new prospects for tumor diagnosis and precision treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70772","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care Screening","authors":"Sarina Madhavan,&nbsp;Allan Hackshaw,&nbsp;Earl Hubbell,&nbsp;Ellen T. Chang,&nbsp;Anuraag Kansal,&nbsp;Christina A. Clarke","doi":"10.1002/cam4.70776","DOIUrl":"https://doi.org/10.1002/cam4.70776","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Blood-based tests present a promising strategy to enhance cancer screening through two distinct approaches. In the traditional paradigm of “one test for one cancer”, single-cancer early detection (SCED) tests a feature high true positive rate (TPR) for individual cancers, but high false-positive rate (FPR). Whereas multi-cancer early detection (MCED) tests simultaneously target multiple cancers with one low FPR, offering a new “one test for multiple cancers” approach. However, comparing these two approaches is inherently non-intuitive. We developed a framework for evaluating and comparing the efficiency and downstream costs of these two blood-based screening approaches at the general population level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We developed two hypothetical screening systems to evaluate the performance efficiency of each blood-based screening approach. The “SCED-10” system featured 10 hypothetical SCED tests, each targeting one cancer type; the “MCED-10” system included a single hypothetical MCED test targeting the same 10 cancer types. We estimated the number of cancers detected, cumulative false positives, and associated costs of obligated testing for positive results for each system over 1 year when added to existing USPSTF-recommended cancer screening for 100,000 US adults aged 50–79.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with MCED-10, SCED-10 detected 1.4× more cancers (412 vs. 298), but had 188× more diagnostic investigations in cancer-free people (93,289 vs. 497), lower efficiency (positive predictive value: 0.44% vs. 38%; number needed to screen: 2062 vs. 334), 3.4× the cost ($329 M vs. $98 M), and 150× higher cumulative burden of false positives per annual round of screening (18 vs. 0.12).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A screening system for average-risk individuals using multiple SCED tests has a higher rate of false positives and associated costs compared with a single MCED test. A set of SCED tests with the same sensitivity as standard-of-care screening detects only modestly more cancers than an MCED test limited to the same set of cancers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Chemotherapy for Post-Menopausal Women With Early Breast Cancer Seems Not to Result in Clinically Significant Changes in Thyroid Function”","authors":"","doi":"10.1002/cam4.70766","DOIUrl":"https://doi.org/10.1002/cam4.70766","url":null,"abstract":"<p>Marina D, Buch-Larsen K, Gillberg L, et al. Chemotherapy for post-menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function. <i>Cancer Med</i>. 2024; 13:e70015. doi:10.1002/cam4.70015</p><p>The authors have unfortunately identified an error in the <b>Methods section (page 3 of 12)</b>, where we incorrectly described the assay as <b>“immunohistochemistry” instead of the correct term “immunoassay.”</b> The accurate sentence should read “Thyroid parameters (s-TSH, s-TT4, s-FT4, s-TT3) were analyzed by <b>immunoassay</b>; s-TgAb and s-TPOAb were analyzed by immunofluorometry, whereas s-TRAb was analyzed by electrochemiluminescence immunoassay.”</p><p>Additionally, this error appears two times in the <b>Discussion section (page 9 of 12)</b>, where <b>“immunohistochemistry” should also be replaced with “immunoassay.”</b> The accurate sentences should read:</p><p>“Our study group conducted an analysis of thyroid hormones using <b>immunoassay</b>, which was the most affordable assay and readily available at a low cost in our department.”</p><p>“It has been documented that free thyroid hormones measured by LC–MS/MS correlate better with log-transformed TSH than those measured by <b>immunoassay</b>, particularly in certain patient groups.”</p><p>Furthermore, in <b>Supplementary Table S1 (page 3 out of 12)</b>, the assay type for the measurements of TSH, TT4, FT4, and TT3 should be <b>corrected again from “immunohistochemistry” to “immunoassay.”</b> The corrected table can be found in the online Supporting Information.</p><p>We sincerely apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70766","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020","authors":"Laure Vincent,&nbsp;Olivier Decaux,&nbsp;Aurore Perrot,&nbsp;Bruno Royer,&nbsp;Thomas Chalopin,&nbsp;Arthur Bobin,&nbsp;Margaret Macro,&nbsp;Denis Caillot,&nbsp;Lionel Karlin,&nbsp;Caroline Jacquet,&nbsp;Cécile Sonntag,&nbsp;Mohamad Mohty,&nbsp;Laurent Frenzel,&nbsp;Arnaud Jaccard,&nbsp;Salomon Manier,&nbsp;Laurence Sanhes,&nbsp;Driss Chaoui,&nbsp;Philippe Moreau,&nbsp;Ronan Garlantézec,&nbsp;Nathalie Texier,&nbsp;Chanaz Louni,&nbsp;Zakaria Maarouf,&nbsp;Herve Avet Loiseau,&nbsp;Cyrille Hulin,&nbsp;Karim Belhadj Merzoug","doi":"10.1002/cam4.70619","DOIUrl":"https://doi.org/10.1002/cam4.70619","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Background</h3>\u0000 \u0000 <p>Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real-world impacts need to be assessed over the long term.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>EMMY is a non-interventional, prospective dynamic cohort, conducted in France, since 2017, with 900 patients enrolled each year. Newly diagnosed MM (NDMM) who initiated a treatment from 2017 to 2020 are here described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1036 non-transplant eligible (NTE) patients (median age: 74.9 years) and 561 patients who received autologous stem cell transplantation (ASCT) (median age: 60.6 years) were enrolled. For ASCT patients, a shift in induction treatment from bortezomib-thalidomide-dexamethasone (VTd) (29.1%) to bortezomib-lenalidomide-dexamethasone (VRd) (55.1%) marked the period. Maintenance treatment with R after ASCT became a standard (75% of patients). In NTE patients, R-based regimens were increasingly used from 29.4% in 2017 (of whom Rd.: 17.0%, VRd: 10.6%) to 73.3% in 2020 (of whom Rd.: 21.8%, VRd: 48.5%). Median progression-free survival (mPFS) was 46.5 months (95% CI: 37.8–50.6) and 18.7 months (95% CI: 16.3–20.8) in ASCT and NTE patients, respectively. In the ASCT group, patients treated with and without R maintenance had a mPFS of 51.8 (95% CI: 44.1–NA) and 29.6 months (95% CI: 21.8–40.9), respectively. In the NTE group, the mPFS was 26.3 (95% CI: 21.9–30.9) and 14.6 months (95% CI: 11.9–17.7) in patients who received an R-based and non-R-based regimen, respectively. The estimated 48-month overall survival rates were 89% (95% CI: 84.5–92.2) and 63% (95% CI: 58.5–67.1) for ASCT and NTE patients, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The 2017–2020 period was marked by the expansion of R use in both NDMM ASCT and NTE patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades","authors":"Zerubbabel K. Asfaw,&nbsp;Tirone Young,&nbsp;Cole Brown,&nbsp;Mehek Dehdia,&nbsp;Lily Huo,&nbsp;Kunal K. Sindhu,&nbsp;Stanislav Lazarev,&nbsp;Robert Samstein,&nbsp;Sheryl Green,&nbsp;Isabelle M. Germano","doi":"10.1002/cam4.70673","DOIUrl":"https://doi.org/10.1002/cam4.70673","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (<i>p</i> = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, <i>p</i> = 0.012), higher median citations (30 vs. 19, <i>p</i> &lt; 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, <i>p</i> &lt; 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (<i>p</i> &lt; 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70673","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms","authors":"Yi Liu,&nbsp;Bingxian Bian,&nbsp;Shiyu Chen,&nbsp;Bingqian Zhou,&nbsp;Peng Zhang,&nbsp;Lisong Shen,&nbsp;Hui Chen","doi":"10.1002/cam4.70659","DOIUrl":"https://doi.org/10.1002/cam4.70659","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer (GC) is considered a highly heterogeneous disease, and currently, a comprehensive approach encompassing molecular data from various biological levels is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study conducted different analyses, including the identification of differentially expressed genes (DEGs), weighted correlation networks (WGCNA), single-cell RNA sequencing (scRNA-seq), mRNA expression-based stemness index (mRNAsi), and multiCox analysis, utilizing data from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Subsequently, the machine learning algorithms including least absolute shrinkage and selection operator (LASSO) regression and random forest (RF), combined with multiCox analysis were exploited to identify hub genes. These findings were then validated through the receiver operating characteristic (ROC) curve and Kaplan–Meier analysis, and were experimentally confirmed in GC samples by reverse transcription–polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Integrated analysis of TCGA and GEO databases, coupled with LASSO regression and RF algorithms, allowed us to identify 18 hub genes encoding differentially expressed secreted proteins in GC. The results of RT-PCR and bioinformatics analysis revealed four promising biomarkers with optimal diagnostic and prognostic potential. ROC analysis and Kaplan–Meier curves highlighted CHI3L1, FCGBP, VSIG2, and TFF2 as promising biomarkers for GC, offering superior modeling accuracy. These findings were further confirmed by RT-PCR and ELISA, affirming the clinical utility of these four biomarkers. Additionally, CIBERSORT analysis indicated a potential correlation between the four biomarkers and the infiltration of B memory cells and Treg cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study unveiled four promising biomarkers present in the serum of patients with GC, which could serve as powerful indicators of GC and provide valuable insights for further research into GC pathogenesis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}